How to Assess Clinical and Regulatory Risk During Due Diligence

In the fast-moving world of life sciences, mergers, acquisitions, and strategic partnerships are often defined by one critical step: due diligence. Whether evaluating a biotech startup with an innovative molecule or a mid-size pharmaceutical firm with a mature product portfolio, investors and acquirers must systematically identify and quantify clinical and regulatory risks. These risks, if overlooked, can derail timelines, inflate costs, and jeopardize approvals — even after a deal closes.

Assessing these risks requires not just technical knowledge but also structured processes, multidisciplinary expertise, and a forward-looking perspective. This article outlines the key dimensions of effective clinical and regulatory risk assessment during due diligence — a process that companies like Eliquent have emphasized as central to sound life sciences investment.

1. Understanding the Scope of Clinical and Regulatory Due Diligence

Clinical and regulatory due diligence aims to determine whether a company’s assets — typically investigational drugs, medical devices, or diagnostics — are on a credible path to approval and market success. This goes beyond reviewing documents. It involves assessing scientific validity, regulatory compliance, data integrity, and organizational capability.

At its core, due diligence should answer three essential questions:

1. Is the science sound? Are the mechanisms of action, target selection, and preclinical models credible and supported by reproducible data?
2. Is the regulatory path viable? Has the company aligned with applicable guidance from the FDA, EMA, MHRA, or other regulatory agencies?
3. Is the clinical evidence sufficient? Do the study designs, endpoints, and safety data support the intended claims or indications?

Firms like Eliquent often advise clients to establish risk matrices early, mapping potential issues across clinical, regulatory, and operational domains before proceeding to valuation.

2. Evaluating Clinical Risk: From Study Design to Data Integrity

Clinical risk assessment starts with the quality and integrity of data. Key areas of focus include:

• Study Design and Protocols: Review whether clinical trials are statistically powered and aligned with regulatory expectations. Poorly designed studies may require replication, delaying approvals.
• Endpoints and Outcomes: Assess if endpoints are clinically meaningful and validated. Regulators increasingly prioritize patient-relevant outcomes and real-world evidence.
• Adverse Event Profiles: Early-stage safety signals, if not contextualized properly, can amplify perceived risk. Comprehensive safety monitoring and transparent reporting are critical.
• Data Integrity and Traceability: Ensure that clinical data complies with Good Clinical Practice (GCP) standards, with full traceability from source documentation through analysis.

A red flag in this area might be inconsistent adverse event reporting or missing raw datasets — both signs of potential compliance risk. Companies performing due diligence should request direct access to audit trails, electronic data capture systems, and third-party monitoring reports.

3. Assessing Regulatory Risk: Alignment and Compliance

Regulatory risk often stems from misalignment with authorities or inconsistent interpretation of guidelines. Evaluating this requires a deep understanding of past and ongoing interactions with agencies.

• Regulatory Correspondence: Review formal communications such as FDA meeting minutes, clinical hold letters, and EMA scientific advice. These documents reveal the regulator’s perspective on key risk areas.
• Submission Quality: Investigate whether prior regulatory submissions (INDs, NDAs, MAAs, 510(k)s, etc.) were timely, complete, and compliant. Poorly structured dossiers can indicate weak internal regulatory functions.
• Global Strategy: For companies seeking multi-regional approvals, assess whether their regulatory strategies are harmonized across markets or fragmented by region.

Another often-overlooked area is post-market compliance. Even for marketed products, inspection histories, labeling discrepancies, and pharmacovigilance records can expose hidden liabilities.

4. The Role of Cross-Functional Expertise

Clinical and regulatory due diligence is inherently multidisciplinary. Beyond scientists and clinicians, it should involve biostatisticians, regulatory writers, quality assurance specialists, and legal counsel. Collaboration among these teams ensures that findings are contextualized — a minor data inconsistency might be manageable scientifically but catastrophic legally if it breaches disclosure requirements.

Experienced partners like Eliquent often integrate technical subject matter experts with transaction teams, ensuring that scientific insights translate into actionable business recommendations.

5. Quantifying Risk: Frameworks and Scoring Models

Once risks are identified, they must be quantified. A structured scoring framework helps prioritize which issues are deal-breakers and which can be mitigated post-acquisition.

Common approaches include:

• Probability-Impact Matrices: Mapping risks by likelihood and severity to focus resources on the most critical threats.
• Regulatory Readiness Scores: Evaluating how prepared the company is for its next submission or inspection.
• Clinical Development Risk Indexes: Combining factors like trial stage, patient population, and therapeutic novelty to produce an overall confidence rating.

Investors increasingly expect these risk scores to be supported by objective evidence and clear documentation. Transparency in methodology is key — subjective “gut feel” assessments are no longer sufficient in today’s data-driven environment.

6. Mitigating and Monitoring Risks Post-Transaction

Identifying risk is only the first step. The most successful due diligence outcomes include risk mitigation roadmaps that guide post-transaction integration. These might involve:

• Initiating data remediation or revalidation activities
• Conducting targeted regulatory re-engagements to clarify development pathways
• Enhancing pharmacovigilance systems to ensure compliance after acquisition

Continuous monitoring, through regular audits and milestone-based reviews, ensures that identified risks remain under control as development progresses.

In Short

Effective assessment of clinical and regulatory risk during due diligence is both an art and a science. It demands critical thinking, transparency, and collaboration across scientific and business disciplines. As the regulatory environment grows more complex — with increasing scrutiny on data integrity, patient safety, and real-world performance — the importance of rigorous, structured due diligence cannot be overstated.

Organizations that approach this process with precision, guided by experienced partners such as Eliquent, not only protect their investments but also lay the groundwork for compliant, ethical, and ultimately successful innovation in life sciences.